• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Can Emerging AI-Guided Software Rein in Scan Times for Cardiac MRI?

Video

In a recent video interview, Raymond Y. Kwong, MD, discussed his clinical experience with the Vista.ai (formerly HeartVista) One Click MRI software and recent research, presented at the Radiological Society of North America (RSNA) conference, that revealed a 31 percent decrease in cardiac MRI scan times for patients with cardiomyopathy or structural heart disease.

For Raymond Y. Kwong, MD, MPH, FACC, FSCMR, long scan times with cardiac magnetic resonance imaging (MRI) can have a significant downstream effect on patient access to this technology. He noted the increased demand for cardiac MRI has led to wait times of three to five weeks for outpatients and four to five days for in-patients to be scheduled for a cardiac MRI.

“These numbers are really unacceptable for patient care from our standpoint,” noted Dr. Kwong, the director of Cardiac Magnetic Resonance Imaging in the Cardiovascular Division of the Department of Medicine at Brigham and Women’s Hospital in Boston, and a professor medicine at Harvard Medical School.

With this in mind, Dr. Kwong recently started using Vista.ai (formerly HeartVista) One-Click MRI, an artificial intelligence (AI)-enabled software that helps improve image quality as well as the efficiency of cardiac MRI procedures. At the recent Radiological Society of North America (RSNA) conference, Dr. Kwong shared his six-month experience with Vista.ai’s One-Click MRI and noted a 31 percent reduction in scan times based on 1,100 consecutive cardiac MRI studies performed between April 2022 and September 2022 for patients with cardiomyopathy or structural heart disease.

When employing full use of the Vista.ai One-Click MRI software, Dr. Kwong found that 90 percent of cardiac MRI studies could be completed in less than 45 minutes in comparison to 25 percent of non-AI-aided studies.

(Editor’s note: This interview was recorded prior to HeartVista’s announcement about the company name change to Vista.ai.)

For more insights from Dr. Kwong, watch the video below.

Recent Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Related Content
© 2024 MJH Life Sciences

All rights reserved.